| Filed On | Filing |
|---|---|
| 02 Jul 2024 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +5 more
Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action of the board... |
| 18 Jun 2024 |
8-K: Other Events
Clinically proven to improve attention function, EndeavorOTC® is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD |
| 29 May 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This AGREEMENT AND PLAN OF MERGER, dated as of May 29, 2024 (this “Agreement” and, such date, the “Agreement Date”), by and among Virtual Therapeutics Corporation, a Delaware corporation (“Parent”), Alpha Merger Sub, Inc., a Delaware cor... |
| 14 May 2024 |
8-K: Results of Operations and Financial Condition
Company announces full voluntary prepayment of debt and termination of Amended & Restated |
| 30 Apr 2024 |
8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +1 more
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results |
| 23 Apr 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Submission of Matters to a Vote of Security Holders
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 29 Feb 2024 |
8-K: Results of Operations and Financial Condition
FY 2023 total revenues of $1.7M, a 420% increase over FY 2022 as EndeavorOTC® gained traction in the market following June 2023 product release |
| 26 Feb 2024 |
8-K: Other Events
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan |
| 21 Feb 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen’s 44th Annual Healthcare Conference on March 4, 2024 |
| 05 Jan 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Dec 2023 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 18 Dec 2023 |
8-K: Other Events
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17 |
| 09 Nov 2023 |
8-K: Results of Operations and Financial Condition
Reports third quarter total revenues of $702 thousand, representing more than 5x growth over |
| 27 Oct 2023 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On October 24, 2023, Akili, Inc. (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the 30 consecutive business days from... |
| 06 Oct 2023 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer |
| 13 Sep 2023 |
8-K: Costs Associated with Exit or Disposal Activities; Other Events
Non-prescription model will increase patient access to clinically-validated non-drug treatments and reduce Akili’s reliance on intermediaries |
| 10 Aug 2023 |
8-K: Results of Operations and Financial Condition
EndeavorRx® prescriptions in pediatric ADHD market grew 27% in Q2 2023 over Q1 2023 |
| 07 Jun 2023 |
8-K: Regulation FD Disclosure; Other Events
Amid growing mental health crisis, the product release enables immediate access to non-drug treatment option as Akili prepares FDA submission |
| 11 May 2023 |
8-K: Results of Operations and Financial Condition
EndeavorRx® prescriptions for children with ADHD increased 32% in Q1 2023 over Q4 2022 |
| 04 May 2023 |
8-K: Submission of Matters to a Vote of Security Holders
On May 2, 2023, Akili, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders voted on the following two proposals: (1) to elect tw... |
Loading...